NVO
Held by
0
portfolios on TandT
Bookmarked by
0
users
Platform exposure
—
13F filers
2
institutions
Market cap
$209.9B
4,427M shares
52-week range
$35.12 – $71.80
31% from low
Exchange
NYSE
ADRC
Borrow rate
0.32%
Easy to borrow
Price (6 mo)
Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
www.novonordisk.com- Employees
- 69,500
- IPO / List date
- Apr 30, 1981
Held by traders on TradeandTell
No one on the platform currently holds NVO.
Super investors & insiders
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 2,881,996 | $159.9M |
| Bridgewater Associatesas of 2025-09-30 | 138,947 | $7.7M |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Dividend history
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-30 | $1.2174 | 2026-04-08 |
| 2025-08-18 | $0.5843 | 2025-08-26 |
| 2025-03-31 | $1.1426 | 2025-04-08 |
| 2024-08-16 | $0.5169 | 2024-08-26 |
| 2024-03-22 | $0.9293 | 2024-04-02 |
| 2023-08-18 | $0.8763 | 2023-08-29 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-09-20 | 2-for-1 |
| 2014-01-09 | 5-for-1 |
| 2007-12-17 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded NVO yet.
$NVO chatter on StockTwits
@Yass93 EU is still around +1%... thats good enough. I think EU is afraid of pullback on US... but the stock is still a great deal at this price so... go $NVO
View on StockTwits ↗
$NVO Whelp euro gave it the good ole college try then let it flop. Hopefully there is a better outcome once the US market opens.
View on StockTwits ↗
$VKTX $NVO $LLY The obesity drug market is currently dominated by Danish drugmaker Novo Nordisk and its American rival Eli Lilly and Co.
View on StockTwits ↗
$NVO big resistance coming up tomorrow. Clearing that is the road to $50, a rejection here could send it back down to $45, good luck.
View on StockTwits ↗
$NVO estimate 14/65 million seniors with Medicare will be eligible getting coverage for the first time in history on obesity treatment. Even if intial ramp up is 1 million population split between Lily and nvo. This will be insane
View on StockTwits ↗$NVO July 1 st. After two weeks the 300k to 500k population sign up initially for the obesity coverage will send this stock through $75
View on StockTwits ↗
$VKTX $AZN $NVO .....Just punching in a few phrase's on Gemini(free site though)....tonight they have 'offered' up AZN as a good fit for some or all of VKTX.....a chunk off the old VKTX seems more plausible at this stage though...anyways...just picking 'its' database for tidbits/crumbs...glta "The "Fixed-Dose Combo" Obsession: At the 2026 ADA meeting, AstraZeneca's R&D leadership explicitly stated their goal is to combine their oral GLP-1 (elecoglipron) with other mechanisms to maximize muscle-sparing weight loss. By acquiring Viking's amylin pipeline, AZN could build powerful, proprietary internal combinations (GLP-1 + GIP + Amylin) that mimic Novo Nordisk's high-potency CagriSema strategy."
View on StockTwits ↗
$NVO wow is it waking up? Can we get back to $70 by year end? That’s just the price 1 year ago
View on StockTwits ↗
$VKTX I think valuation gap was $PFE Bourla problem and he is paying for his stance now. Serious parties that want to compete with $LLY evaluate asset value and once they agree they come up with a journal report to close the gap. I don’t believe $NVO is worried about premium vs getting right asset. Same applies to several others. Something is serious brewing.
View on StockTwits ↗
$TQQQ $MSFT $VRT $NVO is trading in a way that reflects AI momentum continuation. I am staying disciplined and letting the chart confirm the narrative.
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.